We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA flagged deficiencies in corrective actions, testing and documentation during a July/August inspection of UK drug substance and sterile drugmaker Porton Biopharma.